Hims has surged more than 50% this week, as investors focus on the impact of Trump’s Secretary of Health peptide-related policies on the company’s GLP-1 weight-loss drug business transformation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US stock index adjustments to take effect next Monday: Bloom Energy (BE.US) and Everpure (P.US) to be included in S&P 500, changes also for mid- and small-cap stocks
Bloom Energy, Illumina, and Everpure will be included in the S&P 500 index, while several other companies will be added to the S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices.
Is the Federal Reserve repeating the 2022-style rate hikes? Bank of America warns: Rates may return above 5%, suggests shorting two-year U.S. Treasuries.
Bank of America warns: With Waller at the helm, the Federal Reserve may raise interest rates above 5%, potentially repeating the events of 2022.
OpenAI is expected to burn over $278 billion in cash by 2030, with a revenue target of $350 billion over the same period.
OpenAI is expected to generate up to $278 billion in negative free cash flow over the next five years, driven solely by computing power and infrastructure, with cumulative spending projected to reach approximately $856 billion by 2030. The company anticipates revenue of $350 billion in 2030 and $36 billion in 2026, with total revenue from 2026 to 2030 amounting to around $840 billion.
Crypto prices
More
